The mechanism of AOD 9604 in subcutaneous adipose tissue Activation of fat breakdown (lipolysis) AOD 9604 promotes fat breakdown through the following pathways: Activation of the 3-AR signaling pathway: AOD 9604 binds to 3-AR on the adipocyte membrane, activates adenylic acid cyclase (AC), increases the intracellular cyclic adenosine monophosphate (cAMP) level, and thereby activates protein kinase A (PKA)

If pancreatitis is suspected, Wegovy should be discontinued and appropriate diagnostic tests performed urgently Gallbladder problems : Rapid weight loss increases risk of gallstone formation, with cholelithiasis reported in approximately 1.6% of Wegovy users Intestinal obstruction/ileus : Cases have been reported in post-marketing surveillance, particularly in patients with pre-existing GI conditions Management strategies recommended by healthcare professionals include: Eating smaller, more frequent meals rather than large portions Avoiding high-fat, spicy, or heavily processed foods Staying well-hydrated, particularly if experiencing diarrhoea or vomiting, to prevent dehydration and potential acute kidney injury Not lying down immediately after eating to minimise reflux Ensuring adequate fibre intake to prevent constipation Taking the medication on the same day each week to maintain steady levels Most GI side effects improve over time as the body adjusts to the medication, typically becoming less troublesome after 4-8 weeks at each dose level

It is being researched for its potential role in supporting protein synthesis, tissue repair and body composition
The slowed movement of stomach contents can interfere with nutritional intake at a time when adequate nutrition is crucial for healing
10 Suppl: S19